Pressure Mounts on Novo Nordisk’s $16.5B Catalent Buy Amid FTC Review

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.

Scroll to Top